Replies to post #764292 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gabagool,

I ran your comments through the AI BS Detector, and they were identified as bs. 😶

JAMA Oncology DCVax-L


https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/










“They called me Gabagool Research”



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176114523

[j e d]

Man, this is becoming cringeworthy. You present yourself as an uninterested biotech researcher with a relevant PhD, but then have prolonged tit-for-tat arguments on a penny stock forum. Doesn't pass the smell test.

Also, as you know, DCVax's PFS comparison was confounded, so saying

nor does it improve PFS

is dishonest. It did, however, improve OS significantly, which is more important that PFS anyway. POLO not having an effect on OS is more damning that a confounded PFS comparison, as PFS only exists as a proxy for OS. Either you are not a serious researcher or you have a financial interest to spin (or both).

[jesster64]

yes, the last line of defense for the journalist, blame the reader. POLO is a smokescreen. Anything about it has nothing to do with dc-vax.
"DCVax isn’t in treatment guidelines, nor does it have approval, nor does it improve PFS"
you forgot to add it prolongs life

" the authorship of a journal article does not render it immune to criticism", I never said it did. What I am saying is your anonymous criticism is worth less than the opinion of the 73 scientific peers, yet you never mention them in the article. Nice of you to point out vinay prasad, now how about naming some of those who criticize dc-vax in fairness or can't you be bothered?

[The Danish Dude]

… the authorship of a journal article does not render it immune to criticism

Thank God pseudonymity of a hit piece under the guise of the Seeking Alpha short and distort scam banner, does somewhat offers that.

As Joshua Mitts wrote in his Short and Distort paper.

https://download.ssrn.com/20/02/19/ssrn_id3541328_code1806223.pdf

In this paper, I show how pseudonymity undermines reputational accountability in financial markets. I examine 2,900 attack articles against mid- and large-cap firms published on a website, Seeking Alpha, and show that pseudonymous ones are followed by stock-price declines and sharp reversals.

Thanks for the two contributions you misinterpret as analysis.

The first one I dissected, digested and spat out, so please spare us any nonsense of anyone wasting their time doing it again.

For any long with half a brain about due diligence, your hit piece was beneath amateurism.

Which is how pseudonymous short and distort hit pieces gets validated on Seeking Alpha in the first place.

I’ve seen quality pieces getting turned down, on idiotic grounds, simply because the “ticker” was in the short and distort target.

You wouldn’t want to publish stuff about a naked shorted company that actually contained positives.

I commend you on when your hit piece was published right in time to counter an upswing thus justifying market makers manipulation.

Welcome to the board by the way.

You are gonna fit right in 👍🏻